Granulosa cells in a mature ovarian follicle have an abundance of LH/hCG receptors that respond rapidly to an ovulatory surge in gonadotropins. Within minutes, membrane signal transduction sets in motion metabolic changes that lead to follicular rupture. This study provides evidence that the initial ovarian response to such an ovulatory stimulus includes induction of the immediate-early transcription factor gene for early growth response protein-1 (Egr-1). Immature Wistar rats were primed with 10 IU equine CG (eCG), sc, and 48 h later the 12-h ovulatory process was initiated by 10 IU hCG, sc. Ovarian RNA was extracted at 0, 0.5, 1, 2, 4, 8, 12, and 24 h after the primed animals were injected with hCG. The RNA extracts were used for RT-PCR differential display for random detection of gene expression in the stimulated ovarian tissue. Northern analysis of one of the differentially amplified complementary DNAs confirmed that it was part of a gene that was significantly up-regulated within 1 h after the ovaries had been stimulated by hCG. Maximum transcription was at 4 h after hCG, and expression declined to 0 h control levels by 24 h after hCG. Subcloning and sequence analysis revealed that the complementary DNA matched the gene for Egr-1. In situ hybridization indicated that the Egr-1 messenger RNA was in the granulosa layer of mature follicles. Western blotting confirmed the temporal pattern of Egr-1 expression detected by differential display, Northern analysis and in situ hybridization. The Egr-1 protein is approximately 84 kDa. In conclusion, the data show that expression of the zinc finger transcription factor Egr-1 is an early event in the cascade of inflammatory-like changes that occur in an ovulatory follicle in response to a trophic hormone.
A MATURE OVARIAN follicle contains granulosa cells that express a substantial number of LH/hCG receptors (1, 2) . The signal transduction processes that are initiated by these receptors at the time of the ovulatory surge in LH (and FSH) induce several dynamic changes in follicular cell function. Along with the resumption of meiotic activity in the oocyte, there is induction of granulosa cell differentiation into progesterone-secreting lutein cells. Also, the fibroblasts in the thecal layers around the periphery of a follicle undergo transformation from quiescence to motility as they proliferate through the membrana propria toward the interior of the follicle, where they lay down a connective tissue framework to support the developing luteal tissue (1) . Thus, acute hormonal stimulation of a mature ovarian follicle leads to substantial cellular changes that convert a cavernous ovulatory follicle into a solid mass of luteal cells within only 24 -48 h in most mammals. This transformation of an ovarian follicle into a corpus luteum involves distinct ovarian cell types, diverse signaling pathways, and temporally controlled expression of specific genes (3).
When extracellular ligands such as trophic hormones stimulate cytokinetic phenomena such as the ovulation/luteinization transformation, the target tissue response involves alterations in gene expression in the activated cells. The genomic response usually includes the induction of immediate-early transcription factor genes such as early growth response protein-1 (Egr-1; also known as Krox-24, NGFI-A, zif/268, cef5, and TIS8) gene, and/or the c-fos and c-jun genes (4, 5) . Although rapid (albeit transient) Egr-1 gene induction is a common component of the response to mitogenic hormones that stimulate cells to undergo G 0 -G 1 transition (5, 6) , this transcription factor is also known to increase in cells that are only differentiating without dividing, such as LH-secreting cells in the pituitary (7) . After it is translated, the Egr-1 protein translocates into the nucleus and functions as a zinc finger transcription factor to regulate the expression of an estimated 80 -100 other genes, increasing their transcription rates as much as 100-fold (4, 5) .
The present report characterizes, for the first time, ovarian expression of the Egr-1 gene during the early stages of the ovulatory process in the gonadotropin-primed immature rat. This predictable gene expression was discovered during differential display RT-PCR analysis of messenger RNAs (mRNAs) that are expressed in the ovary at the time of ovulation. The report describes the temporal and spatial patterns of expression of the gene during a periovulatory period ranging from 12 h before to 12 h after follicular rup-ture. It also assesses the effects of progesterone and PG synthesis on expression of the Egr-1 gene.
Materials and Methods

Animal tissue and animal injections
Immature Wistar rats were induced to superovulate by eCG and hCG treatment as described previously (8) . Ovarian RNA was extracted primarily at the periovulatory intervals of 0, 2, 4, 8, 12, and 24 h after hCG administration. However, in a subsequent experiment, RNA was also extracted at 0.5 and 1 h after hCG to identify more precisely the onset of Egr-1 mRNA expression. All ovaries were extirpated immediately after exposing the rats to excess CO 2 . The nucleic acid extracts were used for differential display and Northern blotting. Indomethacin and epostane were injected sc, also as described previously (8) . These antiovulatory agents were administered at 3 h after hCG in doses of 1.0 and 5.0 mg, respectively. The ovaries of indomethacin-and epostane-treated animals that were used for Northern blots were taken at 4 h after treatment of the animals with hCG, because this was the time of maximum Egr-1 RNA expression. The animals were acquired, retained, and used in compliance with NIH guidelines and with the approval of the institutional animal care review committee.
Ovarian PGE 2 and progesterone vs. ovulation rate
Ovaries for PGE 2 and progesterone RIAs were extirpated at 8 h after hCG treatment, because at this time rat ovaries synthesize maximal amounts of these two ovulation-related agents (9) . PGE 2 was assayed as described previously (9) . Progesterone levels in aqueous extracts of homogenized ovaries were assayed according to instructions in a commercial RIA kit for this steroid (TKPG1, Diagnostic Products, Los Angeles, CA). A reagent kit (P5656, Sigma, St. Louis, MO) was used to perform protein assays on aliquots of each RIA sample. The amount of eicosanoid or steroid per sample was expressed as nanograms per mg protein in each sample. The ovulation rate in the experimental animals was determined by a procedure that also has been described previously (8) . Ova were counted in the oviducts at 24 h after hCG administration, because this is the optimal time to quantitate ovulation rate (our unpublished observation).
Differential display protocols for detection of Egr-1
The steps of the differential display were carried out as described previously (8) . In brief, RNA was extracted by a standard guanidine isothiocyanate/cesium chloride procedure. RT-PCR was performed using an RNAimage Kit (G502, GenHunter Corp., Nashville, TN). The specific primer set that yielded differentially expressed complementary DNA (cDNA) for Egr-1 was 5Ј-HTTTTTTTTTA-3Ј and 5Ј-HTAGAGCG-3Ј, where H represents a HindIII restriction site attached to the primers. After extraction and reamplification of the differentially expressed cDNA, a standard Northern analysis was performed to confirm the ovulation-specific expression of the parent mRNA for Egr-1. The unique cDNA fragment was subcloned using a pCR-TRAP Cloning System (P404, GenHunter), and a cloning colony containing the Egr-1 cDNA was identified by secondary Northern analysis. Manual sequencing of the cDNA was performed using a Sequenase version 2.0 DNA sequencing kit (US70770, Amersham Pharmacia Biotech, Piscataway, NJ). In situ hybridization was performed as described previously (8) .
Western blot analysis of Egr-1
Ovaries were extirpated from rats at the indicated periovulatory intervals, and granulosa cells were isolated from the residual ovarian compartment by puncture with a 26-gauge needle. Whole cell extracts were prepared from cells and tissue by homogenizing in 10 mm Trisbuffer (pH 7.5) containing 0.4 m NaCl, 1 mm dithiothreitol, and 10% glycerol. The Tris buffer also contained phosphatase and protease inhibitors in amounts of 1 mm EDTA, 1 mm phenylmethylsulfonylfluoride, 1 mm orthovanadate, 10 mm NaF, 10 m leupeptin, 10 m pepstatin, and 1 g/ml aprotinin. Protein extracts (50 g) were resolved by reducing SDS-PAGE on a 10% acrylamide gel and transferred to polyvinylidene difluoride membranes (Immobilon-P, Millipore Corp., Bedford, MA). To minimize nonspecific binding, the membranes were shaken for 1 h in 3% nonfat milk, incubated for 1 h in 3% milk with 0.5 g/ml Egr-1 antiserum (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), and subsequently washed in TBST [10 mm Tris (pH 7.5), 150 mm NaCl, and 0.05% Tween-20]. Blots were then incubated for 1 h with 1:10,000 horseradish peroxidase-linked antirabbit IgG (Amersham Pharmacia Biotech). After incubation, the membranes were washed again in TBST, and Egr-1 detection was performed according to the manufacturer's instructions.
Statistical analysis
The intensity of the signals from the Northern blots was quantitated by the NIH Image densitometry program, as described previously (8) . Numerical data are presented as the mean Ϯ sem. The significance of the differences among means was determined by Duncan's multiple range tests after a completely randomized one-way ANOVA of the means of the groups. The cut-off between significant and not significant was P ϭ 0.05.
Results
Differential display of Egr-1 cDNA during the ovulatory process
After RT-PCR, the subpopulations of radioactively labeled cDNAs that were generated from RNA extracts at each of the six stages of the periovulatory period were separated from one another by electrophoresis on a polyacrylamide gel. The autoradiograph of these PAGE results revealed differentially expressed cDNA bands that were present at 2, 4, 8, and 12 h after hCG treatment, but were not conspicuous at 0 h or at 24 h into the ovulatory process ( Fig. 1) . Therefore, the most intense cDNA band (i.e. the band in the 4 h lane) was excised 
Northern analysis of Egr-1 mRNA expression during ovulation
The Northern blots revealed a pattern of mRNA expression during ovulation comparable to the differential display autoradiograph (Fig. 2) . In view of the fact that the initial Northern analysis revealed that the onset of Egr-1 mRNA expression began at some point between 0 and 2 h after the hCG stimulus, a subsequent set of RNA extractions included time points of 0.5 and 1 h. As the most intense Northern signal was at 4 h, the value for this lane was arbitrarily set at 100%, and the densities at the other times during the periovulatory period were expressed as fractions of that maximum. Accordingly, the NIH Image program was used to digitize all of the bands on the Northern blots, and the ratio of the density of each experimental band to its corresponding ␤-actin control band was calculated for each lane. Based on these calculations, Egr-1 gene expression increased 39-fold within 4 h after the ovulatory process was initiated by an injection of hCG into the animals. Subsequently, at 24 h after hCG (i.e. during early luteal development), Egr-1 gene expression declined to a level that was not significantly different from the 0 h control value.
Sequence of the cDNA fragment for Egr-1
After hCG-induced expression of the Egr-1 gene was confirmed by Northern analysis, the cDNA fragment of this gene was subcloned and sequenced. The length of this RT-PCRgenerated cDNA was 353 bp. The NCBI accession number for this fragment is AF023087. The cDNA fragment is essentially identical to a segment of a gene that has been cloned from rat pheochromocytoma cells (E-value ϭ e Ϫ175 compared with the Egr-1 gene at NCBI accession no. M18416). Also, the fragment is highly homologous with Egr-1 genes cloned from the mouse (E-value ϭ e Ϫ106 compared with NCBI accession no. M20157) and the human (E-value ϭ e Ϫ96 compared with NCBI accession no. NM_001964). Based on information in the NCBI database about the Egr-1 gene, the 353-bp fragment isolated in this study is a segment that is downstream from the open reading frame for the Egr-1 protein.
Effects of indomethacin and epostane on Egr-1 gene expression
For these tests, Northern blots were prepared from RNA extracted from control ovaries at 0 and 4 h after injection of hCG or extracted from experimental ovaries taken at 4 h after hCG from rats that had been treated 1 h earlier with ovulation-inhibiting doses of indomethacin or epostane. The experimental interval of 4 h after hCG was selected because this time coincided with the time of maximum expression of the Egr-1 gene (Fig. 2) . The signal density (normalized against the ␤-actin control) of the 4 h control lane was arbitrarily set at 100% (Fig. 3) . There was minimal expression of Egr-1 mRNA at 0 h, but substantial expression at 4 h. In animals treated with the antiovulatory agent indomethacin, which blocks prostanoid synthesis, signal density was not significantly different from the 4 h control value. Animals treated with the antiovulatory agent epostane, which blocks progesterone synthesis, had a signal density that was moderately higher than yet statistically different from the 4 h control value. The ovulation rates in parallel groups of animals treated with either indomethacin or epostane were significantly lower, i.e. were inhibited by these agents (Fig. 3) . In additional parallel groups of animals, indomethacin significantly inhibited ovarian PGE 2 synthesis, and epostane significantly inhibited ovarian progesterone synthesis (Fig. 3) . Thus, indomethacin and epostane inhibited ovarian prostanoid and steroid synthesis, respectively, in a predictable manner, without affecting Egr-1 gene expression.
Localization of Egr-1 mRNA expression by in situ hybridization
In situ hybridization confirmed the temporal pattern of Egr-1 mRNA expression that was observed in the differential display autoradiograph and the Northern analysis. There was minimal signal from the 0 h control ovaries, a strong signal at 2-4 h after hCG treatment, a declining signal at 8 -12 h, and negligible signal at 24 h (Fig. 4) . Hybridization was localized in the granulosa layer of the larger follicles along with what appeared to be some hybridization in the theca interna (Fig. 5) . A number of smaller follicles (located mainly in the center of the ovaries) had no detectable Egr-1 mRNA. Most of the other smaller follicles that did exhibit hybridization had thicker granulosa layers, indicating that these probably were large mature follicles that happened to be sectioned on a plane that was above or below their maximum diameter.
FIG. 2.
Amount of ovarian Egr-1 mRNA as determined by intensity of Northern blot signals at eight intervals of the periovulatory period after hCG administration. Solid dots represent the mean value of six Northern blots prepared from three separate RNA extractions from three batches of rats. Open dots represent the mean of two Northern blots that included RNA extracted at 0.5 and 1.0 h after hCG simultaneously with one of the above three RNA extractions. The signal density at 4 h was arbitrarily set at 100%. An actual Northern analysis of the Egr-1 cDNA along with its ␤-actin control are shown below the graph. Note that the greatest intensity is at 4 h after hCG. a, Significant difference from 0 h control.
Western analysis of Egr-1 translation during ovulation
Western blotting revealed that translation of the Egr-1 gene product coincided with the temporal pattern of Egr-1 mRNA expression observed by Northern analysis and in situ hybridization. There was negligible translation at 0 h after hCG treatment, and the strongest signal was at 4 h (Fig. 6) .
As predicted by the in situ data, the isolated granulosa cells evinced a substantial amount of Egr-1. The modest expression of Egr-1 in the residual ovarian tissue may have been generated by cells in the theca interna, but we cannot rule out the possibility that the source of this Egr-1 was granulosa cells that invariably remain in the residual portion of the ovary. The size of the translated protein was 84 kDa.
Discussion
A wide variety of extracellular stimuli are known to activate phosphorylation-dependent membrane-signaling pathways that program cellular responses to provocation.
FIG. 3.
Comparison of the Egr-1 mRNA signal from Northern blots with data on ovulation rate and PGE 2 and progesterone levels in the ovaries from animals that were treated with either 1 mg indomethacin (Indo) or 5 mg epostane (Epo), administered at 3 h after hCG. Ovarian RNA was extracted at 4 h after hCG treatment, because this is when Egr-1 gene expression was at a peak level. In parallel groups of rats, ovarian PGE 2 and progesterone were assayed at 8 h after hCG, because this is close to the time of maximum synthesis of these agents before follicular rupture. In additional rats, ovulation rate was determined by counting ova in the oviducts at the optimal time of 24 h after hCG. The bar graphs that quantitate Northern blot data are based on NIH Image analyses of four different Northern blots that were prepared from one RNA extraction from experimental groups consisting of seven rats each, i.e. RNA extracts were pooled from seven pairs of ovaries from seven rats. The signal from the 4 h control lane was arbitrarily set at 100% OD to compare the intensities of signals from four different Northern blots. In parallel groups of rats, the ovulation rate was determined at 24 h after hCG. a, Significant difference from 0 h control; b, significant difference from 4, 8, and 24 h controls. Such diverse stimuli include mitogens, morphogens, antigens, neurotransmitters, serum, radiation, and hormones. In instances when a stimulus provokes reactions such as mitosis, differentiation, immune responses, action potentials, or inflammatory reactions, the signal transduction processes in the affected cells rapidly converge on the genome to induce the so-called immediate-early gene response. In essence, this early response consists of the expeditious induction of one or more genes that serve as transcription factors that function to activate a cell-specific repertoire of other genes to carry out the ultimate cellular response to the original stimulus. The best known early response genes are c-fos, c-jun, and Egr-1 (4, 5, 10 -12) . Therefore, further characterization of the Egr-1 gene and its protein product is in order in view of the present evidence of ovarian expression of this gene in response to an ovulatory dose of gonadotropic hormone as well as the subsequent inflammation and differentiation associated with ovulation and luteinization (1) .
Transcription of the Egr-1 gene appears to be regulated by multiple signal transduction processes, including the protein kinase C pathway (4). However, the protein kinase A pathway is the most likely path activated by the LH surge in granulosa cells (2, 3) . The promoter region of the Egr-1 gene contains an Sp1-binding site that can confer trans-activation by Sp1 as well as by chicken ovalbumin upstream promoter transcription factor (COUP-TF) (13) . Sp1 is expressed at high levels in granulosa cells, and Sp1-binding sites in the promoters of several ovarian-expressed genes have been shown to confer FSH and LH inducibility (2, 14) . In some cells, the activation process occurs within minutes. For example, in quiescent fibroblasts that have been stimulated by FCS, there is detectable Egr-1 expression as early as 10 min. In this 3T3 cell model, expression reaches a peak within 30 min and then declines to basal levels by 3-4 h (4). In contrast, ovarian expression of Egr-1 mRNA and its protein product appears to peak approximately 4 h after initial stimulation of the ovulatory process by hCG, and expression of this immediateearly gene does not return to basal level until sometime between 12 and 24 h after hCG. The difference in the relative time course of Egr-1 expression in the ovary compared with that in 3T3 cells in culture may depend on the time required in vivo to increase intracellular levels of hormone, the stage of cell differentiation, or other contextual controls in ovarian cell function. Importantly, granulosa cells of preovulatory follicles respond to LH (or hCG) by rapid exit from the cell cycle and rapid entry into a program of terminal differentiation to luteal cells (15, 16) , whereas the 3T3 cell model is poised for cell proliferation (4). It has been suggested that the poststimulus return to the basal level is the effect of some autoregulatory mechanism (4).
The Egr-1 gene product is a member of the zinc finger family of transcriptional regulators that bind specific sequence motifs in gene promoters. Egr-1 is unique in that it can regulate transcription of some genes positively while affecting other genes negatively (4, 11) . Also, it should be noted that Egr-1 has a serine-and threonine-rich repressor domain that may dominate the transcriptional phenotype of the Egr-1 molecule in the absence of phosphorylation activity that is usually generated by signal transduction processes. This possible bifunctional nature of Egr-1 has been described in more detail previously (4) . The importance of the present discussion to future studies on ovarian genes regulated by Egr-1 is that target genes may be either activated or repressed, depending on the pattern of phosphorylation of the Egr-1 transcription factor as well as the promoter composition of the target genes.
It is interesting to note that the immediate-early gene re- sponse that generates Egr-1 includes a slightly deferred induction of genes for NGFI-A-binding proteins, a family of corepressors that binds directly to Egr-1 and repress Egr-1-mediated transcription (17) (18) (19) . Thus, the cascade of transcriptional activity that is induced by Egr-1 is transient, not just because Egr-1 gene expression is down-regulated, but also because the Egr-1 protein interaction with general transcriptional effectors becomes altered. Such transient transcriptional activity is relevant to the present experimental model because the ovulatory process has been likened to an early transitional phase of the luteinization process that is induced by gonadotropic hormones (1, 2). Therefore, it is possible that the downstream repertoire of Egr-1-induced growth signals could include a subset of genes that is responsible for temporary degradation of the ovarian follicle as it metamorphoses into a functional corpus luteum. The ubiquitous nature of Egr-1 expression as an early response to growth signals suggests that this zinc finger transcription factor has a pivotal role in a cascade of gene expression in cells that have been induced to undergo proliferation, differentiation, or responses to inflammatory-like signals. There is a growing list of physiologically relevant genes that are now recognized as targets for Egr-1 (4, 5, 7, 20, 21) . Some targets that are related to proliferative responses include the thymidine kinase gene that peaks during late G 1 ; various growth factor genes, such as platelet-derived growth factor and fibroblast growth factor; the interleukin genes; and the tumor necrosis factor genes. Others, such as the LH␤ gene, the family of cell surface adhesion protein genes for CD44, and genes for several matrix metalloproteinases (MMPs), are related more to differentiated functions of these cells. The reported relationship among Egr-1, CD44, and a number of MMPs (21-24) is especially intriguing, because this family of proteases has been implicated in the degradative events of ovulation for quite some time (25) . MT1-MMP (i.e. MMP14) is the only one to date that has been shown to have a functional Egr-1 site in its promoter (21) . MMP14, which has been demonstrated in several different types of cells, initially decreases in granulosa cells within 4 h after stimulation by hCG, and then it increases at 12 h after hCG (26) . Therefore, MMP14 might be negatively or positively regulated by Egr-1 in luteinizing granulosa cells. In contrast, ADAMTS-1 (25), MMP19 (26) , and tissue inhibitor of metalloproteinase-1 (26) are all induced by hCG, making them possible targets of Egr-1 in granulosa cells and possibly in theca interna cells. In any event, these and other genes that have been linked to Egr-1 are all candidates for investigation as potential mediators of Egr-1 action in ovarian follicles during the ovulatory process.
The present assessment of ovarian Egr-1 gene expression compared with ovarian PGE 2 and progesterone levels was conducted because of the extensive evidence that the synthesis of such prostanoids and steroids begins to increase in the ovary around 2-3 h after initiation of the ovulatory process by hCG (1, 9) . The existing evidence shows that ovarian PGE 2 and progesterone increase to peak at approximately 8 -10 h after initiating the ovulatory process with hCG. Therefore, it was necessary in this study to rule out the possibility that inhibition of PGE 2 by indomethacin or inhibition of progesterone by epostane might also inhibit Egr-1 gene expression. However, the results make it clear that ovulationinhibiting doses of indomethacin or epostane that significantly reduce ovarian prostanoid and steroid synthesis, respectively, do not affect Egr-1 gene expression during the early stages of the ovulatory process. Thus, it appears that Egr-1 gene expression is not influenced by ovarian prostanoid or steroid production during ovulation.
In conclusion, Egr-1 expression is an immediate-early gene response to gonadotropic hormone action on ovulatory follicles. This gene expression is not dependent on the well known increases in ovarian PG or progesterone synthesis during ovulation. The in situ hybridization data indicate that Egr-1 gene expression is localized in the granulosa layer, and possibly in the theca interna layer, of the larger antral follicles. This suggests that the transcription factor that is translated from the Egr-1 gene may have a central role in regulating the rapid reprogramming of follicular cells to luteal cells (2, 15) . There is also evidence linking Egr-1 activity to sites of inflammation (10, 20, (27) (28) (29) . Therefore, as the ovulatory process is comparable to an acute inflammatory reaction (30), Egr-1 might serve as a mediator of the transient events that cause degradation and rupture of a follicle. It will be of particular interest to assess the potential of Egr-1 protein as a transcription factor for MMP gene expression in follicular tissue at the time of ovulation. Finally, it has been reported that Egr-1 is important for female fertility, because it regulates LH expression in the pituitary gland and LH receptor expression in the ovary (31, 32) . The present results indicate that Egr-1 may also affect fertility by initiating a cascade of ovulation-specific gene expression in ovulatory follicles that have been stimulated by gonadotropic hormone.
